Skip to main content

Table 2 Adverse events of special interest

From: Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)

Adverse Event Symptom/finding/disease
Symptomatic overdose  
Cervical dysplasia  
Other autoimmune disease  
Infusion-associated reactions Anaphylactic reactions
Infections Opportunistic infections, disseminated infections
Diseases of the blood and lymphatic system Leukopenia, Lymphocytopenia, Thrombozytopenia, Idiopathic thrombocytopenic purpura (ITP), Agranulocytosis, Anemia
Liver disease Elevated transaminases
CNS diseases Progressive multifocal leukoencephalopathy (PML)
Renal diseases Glomerulonephritis
  Nephropathies (e.g. Goodpasture Syndrome)
  1. Particular attention should be given to diseases highlighted in bold